476 related articles for article (PubMed ID: 18423779)
1. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
2. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel.
Foote M
Biotechnol Annu Rev; 2007; 13():345-57. PubMed ID: 17875482
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
4. Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.
Guarneri V; Dieci MV; Conte P
Expert Opin Pharmacother; 2012 Feb; 13(3):395-406. PubMed ID: 22263900
[TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
7. nab-Paclitaxel mechanisms of action and delivery.
Yardley DA
J Control Release; 2013 Sep; 170(3):365-72. PubMed ID: 23770008
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
Stinchcombe TE
Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
[TBL] [Abstract][Full Text] [Related]
9. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
Chirgwin J; Chua SL
Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
[TBL] [Abstract][Full Text] [Related]
10. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Lipp HP
Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
[TBL] [Abstract][Full Text] [Related]
11. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
[TBL] [Abstract][Full Text] [Related]
12. Albumin-bound paclitaxel: a next-generation taxane.
Gradishar WJ
Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
[TBL] [Abstract][Full Text] [Related]
13. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
Vishnu P; Roy V
Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
[TBL] [Abstract][Full Text] [Related]
14. Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.
Lluch A; Alvarez I; Muñoz M; Seguí MÁ; Tusquets I; García-Estévez L
Crit Rev Oncol Hematol; 2014 Jan; 89(1):62-72. PubMed ID: 24071503
[TBL] [Abstract][Full Text] [Related]
15. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial.
Dranitsaris G; Coleman R; Gradishar W
Breast Cancer Res Treat; 2010 Feb; 119(3):717-24. PubMed ID: 19495958
[TBL] [Abstract][Full Text] [Related]
16. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Yamazaki S; Sekine I; Saijo N
Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
[TBL] [Abstract][Full Text] [Related]
17. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
Wiedenmann N; Valdecanas D; Hunter N; Hyde S; Buchholz TA; Milas L; Mason KA
Clin Cancer Res; 2007 Mar; 13(6):1868-74. PubMed ID: 17363543
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
Patil Y; Sadhukha T; Ma L; Panyam J
J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
[TBL] [Abstract][Full Text] [Related]
20. Reinvention of chemotherapy: drug conjugates and nanoparticles.
Nguyen-Ngoc T; Raymond E
Curr Opin Oncol; 2015 May; 27(3):232-42. PubMed ID: 25783982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]